DL

Dimple Lalit Tharani

Active Director Director DIN 10876510
DIN 10876510 First appointment Dec 2024
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Dec 2024
Shareholding value •••• Premium profile

About Dimple Lalit Tharani

Data last updated:

Dimple Lalit Tharani is a Director at Aglenova Pharmaceutical Private Limited (since 2024). Aglenova Pharmaceutical Private Limited reported revenue of ₹98,877 (FY 2025).

DIN 10876510
Primary Designation Director
First Appointment 18 Dec 2024
Oldest Company Age 1 yrs
Largest company Aglenova Pharmaceutical Private Limited · ₹98,877 (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director18 Dec 20242024₹98,877 (FY 2025)Active

Board colleagues of Dimple Lalit Tharani

NameDINCompanyDesignation
Rekha Tharani10876509Aglenova Pharmaceutical Private LimitedDirector

Directorship timeline

Open interactive timeline →
Aglenova Pharmaceutical Private Limited
Premium access

Shareholding and investment profile for Dimple Lalit Tharani

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Dimple Lalit Tharani

Dimple Lalit Tharani currently holds 1 directorship: Aglenova Pharmaceutical Private Limited (Director, since 18 Dec 2024, revenue ₹98,877 (FY 2025)).

Dimple Lalit Tharani was first appointed on 18 Dec 2024 as Director at Aglenova Pharmaceutical Private Limited.

The current boards of Dimple Lalit Tharani's companies include Rekha Tharani (Aglenova Pharmaceutical Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available